Glaxo sales fall 60pc in China after regulatory problems

GlaxoSmithKline has seen its sales decline 61 per cent in China in the three months since it hit major regulatory problems in the People's Republic.

GlaxoSmithKline faces sales decline in a three month period Cuson

The decline was described as 'disappointing' by the chief executive, Sir Andrew Witty, who pointed to the scandal as an important reason why customers took their business elsewhere. Glaxo has admitted that some of its personnel might have broken laws. The Chinese police have claimed that up to the equivalent of £300 million may have been used to bribe doctors with regards to Glaxo pharmaceutical products.  

Too early to predict

Commenting on the issue, Sir Andrew said that it was 'too early' to predict the likely cost of total fines, according to The Financial Times. He added that 'our legal position is where it should be at this stage'.

Email your news and story ideas to: news@globallegalpost.com

Top